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Edited by Bernd HelmsAbstract The majority of the human ATP-binding cassette
(ABC)-transporters function in cellular lipid traﬃcking and in
the regulation of membrane lipid composition associating their
dysfunction with human disease phenotypes related to sterol,
phospholipid and fatty acid homeostasis. Based on ﬁndings from
monogenetic disorders, animal models, and in vitro systems,
major clues on the expression, function and cellular localization
of human ABC-transporters have been gained. Here we review
novel lipidomic technologies including quantitative mRNA
expression monitoring by realtime RT-PCR and DNA-micro-
arrays, lipid mass spectrometry, cellular ﬂuorescence imaging
and ﬂow cytometry as promising tools to further deﬁne regula-
tory networks, lipid species patterns and subcellular domains
important for ABC-transporter-mediated lipid traﬃcking.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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disorders1. Introduction
Members of the ATP-binding cassette (ABC)-transporter
superfamily are found throughout most species and represent
one of the biggest protein families described so far. ABC pro-
teins are usually multispan membrane proteins which mediate
the active uptake or eﬄux of speciﬁc substrates, mainly lipo-
philic molecules, across biological membrane systems includ-
ing the plasma membrane, the endoplasmic reticulum, the
Golgi compartment, mitochondria and peroxisomes [1]. The
group of membrane spanning ABC-transporters can be split
into two diﬀerent sections depending on their mode of action.
The active transporters or pumps, such as members of the
ABCB (MDR/TAP) subfamily, couple the hydrolsis of ATP
and the resulting free energy to movement of molecules across
membranes against a chemical concentration gradient [2]. In
contrast, recent work has identiﬁed several ABC proteins,
which show nucleotide binding and a subsequent conforma-
tional change but very low ATP hydrolysis including ABCA1,
the cystic ﬁbrosis membrane conductance regulator (CFTR/
ABCC7) and the sulfonylurea receptors (SUR1/2, ABCC8/*Corresponding author. Fax: +49 941 944 6202.
E-mail address: gerd.schmitz@klinik.uni-regensburg.de (G. Schmitz).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.08.014ABCC9) [3]. To date, 48 human ABC transporters, which
are subdivided into seven subfamilies, have been identiﬁed
and many of these proteins exert their biological activities in
lipid metabolism and are themselves regulated by lipids includ-
ing phospholipids, sterols and fatty acids [4] (Table 1). In the
following chapters, we review genetic diseases in human
ABC-transporters related to lipid metabolism, provide insights
into the regulation and functional characteristics of these lipid
transporters and present novel lipidomic technologies for their
in vitro and in vivo analysis.2. Diseases and phenotypes caused by ABC transporters
Twenty-two out of 48 currently known human ABC proteins
have been linked to human monogenic disorders or cause spe-
cial disease phenotypes (Table 2). Since ABC transporters rep-
resent a combination of enzymes and structural proteins,
homozygous mutations cause severe human diseases, which
are inherited in a recessive manner. As shown in Table 2, these
genetic diseases are found in ﬁve of the seven ABC subfamilies.
In addition, heterozygous mutations and single nucleotide
polymorphisms (SNPs) in ABC transporter genes have been
connected with susceptibility to complex, multigenic disorders,
such as inﬂammatory bowel disease [5] or Alzheimer’s disease
[6]. In the following paragraphs, a selection of important ABC
transporter related inherited disorders with a special focus on
lipid metabolism are presented, including ABCA1, ABCA3,
ABCA7, ABCA12, ABCB4, ABCB11, ABCD1, ABCG5,
and ABCG8.
2.1. ABCA1 and familial HDL deﬁciency
The ABCA1 gene contains 50 exons and is located on chro-
mosome 9q31. Its open reading frame consists of 6783 bp,
encoding a 2261 amino acid protein. Mutations in the human
ABCA1 gene cause familial HDL deﬁciency syndromes such as
classical Tangier disease (Table 2) [7–9]. The most striking fea-
ture of these patients is the almost complete absence of plasma
HDL, low serum cholesterol levels and a markedly reduced ef-
ﬂux of cholesterol and phospholipids from cells. The low HDL
levels seen in Tangier disease are mainly due to an enhanced
catabolism of these HDL precursors [10]. Interestingly, obli-
gate heterozygotes for TD mutations have approx. 50% of
plasma HDL, but normal LDL levels [11]. Studying 13 diﬀer-
ent mutations in 77 heterozygous individuals, Clee et al. de-
scribed a more than threefold risk to develop coronaryblished by Elsevier B.V. All rights reserved.
Table 1
Overview of human ABC gene subfamilies
Gene Alternat. name Domain structure NH2-term. –LL– PDZ-bind. Tissue expression and cellular location Lipid reg. Known or putative transported molecule
ABCA1 ABC1 (TMD-ABC)2 + + Macrophages, liver, brain + Choline-phospholipids and cholesterol
ABCA2 ABC2 (TMD-ABC)2 + + Brain + Estramustine, steroids
ABCA3 ABC3 (TMD-ABC)2 +  Lung, brain, heart, pancreas + Surfactant phospholipids
ABCA4 ABCR (TMD-ABC)2 +  Photoreceptors  N-retinylidene-PE
ABCA5 (TMD-ABC)2 +  Muscle, heart, testes + Sterols
ABCA6 (TMD-ABC)2 +  Liver, lung, heart, brain, ovary + Phospholipids
ABCA7 (TMD-ABC)2 + + Spleen, thymus, bone marrow, peripheral
leukocytes, brain, adrenal glands, uterus
+ Sphingolipids (e.g. ceramide) and
phospholipids
ABCA8 (TMD-ABC)2 +  Ovary, brain 
ABCA9 (TMD-ABC)2 +  Heart, lung, brain, liver, prostate,
ovary uterus
+
ABCA10 (TMD-ABC)2  + Muscle, heart, gastrointestinal tract,
spleen, lung
+
ABCA12 (TMD-ABC)2   Keratinocytes, placenta, testis, lung, brain,
stomach, prostate, lymphocytes
 Lamellar granule lipids and enzymes
ABCA13 (TMD-ABC)2 +  Trachea, testis, bone marrow 
ABCB1 MDR1 (TMD-ABC)2  + Excretory organs, apical membrane + Phospholipids, PAF, aldosterone,
cholesterol, amphiphiles, b-amyloid
peptide
ABCB2 TAP1 TMD-ABC   Ubiquitous, ER  Peptides
ABCB3 TAP2 TMD-ABC   Ubiquitous, ER  Peptides
ABCB4 MDR3 (TMD-ABC)2   Liver, apical membrane + Phosphatidylcholine
ABCB5 (TMA-ABC)2   Ubiquitous 
ABCB6 MTABC3 TMD-ABC   Mitochondria + Fe/S clusters
ABCB7 ABC7 TMD-ABC   Mitochondria  Fe/S clusters
ABCB8 MABC1 TMD-ABC   Mitochondria  Fe/S clusters
ABCB9 TMD-ABC   Heart, brain, lysosomes +
ABCB10 MTABC2 TMD-ABC   Mitochondria  Fe/S clusters
ABCB11 BSEP (TMD-ABC)2   Liver, apical membrane + Monovalent bile salts (e.g. TC)
ABCC1 MRP1 TMD0-(TMD-ABC)2   Lung, testes, PBMC + GSH-, glucuronate-, sulfate-conjugates,
GSSG, sphingolipids, LTC4, PGA1,
PGA2, 17b-glucuronosyl estradiol,
sulfatides, GM1
ABCC2 MRP2 TMD0-(TMD-ABC)2  + Liver + GSH-, glucuronate-, sulfate-conjugates,
bilirubin glucuronide, LTC4,
17b-glucuronosyl estradiol, taurocholate,
taurolithocholate 3-sulfate, anionic drugs
ABCC3 MRP3 TMD0-(TMD-ABC)2   Lung, intestine, liver, basolateral membrane  glucuronate-, sulfate-conjugates,
17b-glucuronosyl estradiol,
taurolithocholate 3-sulfate
ABCC4 MRP4 (TMD-ABC)2   Prostate + Xenobiotics, nucleosides
(ATP/ADP/AMP/Adenosin, GTP/GDP)
ABCC5 MRP5 (TMD-ABC)2   Ubiquitous + Xenobiotics, nucleosides
(ATP/ADP/AMP/Adenosin, GTP/GDP)
ABCC6 MRP6 TMD0-(TMD-ABC)2 Kidney, liver  Anionic cyclopentapeptides
(e.g. BQ123), LTC4, GSH-conjugates
ABCC7 CFTR (TMD-ABC)2  + Exocrine tissue  Chloride ions, ATP
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G. Schmitz et al. / FEBS Letters 580 (2006) 5597–5610 5599artery disease in aﬀected family members and earlier onset
compared to unaﬀected members [12,13]. In addition to the ab-
sence of plasma HDL, patients with genetic HDL deﬁciency
syndromes display accumulation of cholesteryl esters either
in the cells of the reticulo-endothelial system (RES) leading
to splenomegaly and enlargement of tonsils or lymph nodes,
or in the vascular wall, leading to premature atherosclerosis
[14,15]. To date, more than 50 mutations and several single
nucleotide polymorphisms in the ABCA1 gene have been re-
ported [16].2.2. ABCA3 and neonatal surfactant deﬁciency
ABCA3 is a full-size transporter and encodes a 1704 amino
acid protein with the gene located on chromosome 16p13.3.
ABCA3 shows highest expression in the lung but is also ex-
pressed in brain, heart, pancreas and the mammary gland
[17]. The ABCA3 promoter has been partially characterized
and binding of the estrogen receptor has been observed in
human breast cancer cells [18], but no alternatively spliced
mRNA isoforms have been detected so far. Electron micros-
copy studies revealed that in the lung ABCA3 is expressed
exclusively on the limiting membranes of lamellar bodies of
alveolar type II pneumocytes [19] (Fig. 1A). Pulmonary surfac-
tant is a complex mixture of lipids, primarily di-palmitoyl-
phosphatidylcholine and di-palmitoyl-phosphatidylglycerol
with surfactant proteins (SP) that are synthesized by type-II-
pneumocytes. The hydrophobic SP-B and SP-C as well as sur-
factant lipids are assembled and stored in lamellar bodies.
ABCA3 selectively facilitates the transfer of phosphatidylcho-
line, sphingomyelin, and cholesterol to lamellar bodies [20].
ABCA3 mutations have been identiﬁed in full-term newborns
with unexplained respiratory distress syndrome (URDS), asso-
ciated with a defective assembly of lamellar bodies and fatal
surfactant deﬁciency [21,22]. Recently, Brasch et al. identiﬁed
a strong expression of precursors of surfactant protein B, but
only low levels and aggregates of mature surfactant protein
B within electron-dense bodies in type-II-pneumocytes of
URDS patients [23]. Surfactant protein A (SP-A) was localized
in small intracellular vesicles, but not in electron-dense bodies
(Fig. 1A). SP-A and proSP-B were shown to accumulate in the
intraalveolar space, whereas mature SP-B and surfactant pro-
tein C (SP-C) were reduced or absent, respectively. These data
provide evidence that ABCA3 mutations are associated not
only with a deﬁciency of ABCA3 but also with an abnormal
processing and routing of SP-B and SP-C leading to severe
alterations of surfactant homeostasis and respiratory distress
syndrome.2.3. ABCA7 and Sjo¨gren syndrome
The ABCA7 gene consists of 46 exons and overexpression
experiments in human HeLa and HEK293 cells suggest that
ABCA7 is implicated in the eﬄux of ceramide and phospholip-
ids from the cells [24,25], and novel data also demonstrate en-
hanced export of both cholesterol and phospholipids in
ABCA7 transfected HEK293 cells [26]. ABCA7 knockout mice
display a gender dependent reduction in visceral fat and serum
cholesterol levels representing novel insights into the function
of ABCA7 in human lipid metabolism [27]. The ABCA7 gene
is in close proximity to the gene for the minor histocompatibil-
ity antigen HA-1 on chromosome 19p13.3 in a head-to-tail
array with only 1.7 kb distance between the terminal exon of
Table 2
Human ABC transporter genes and corresponding diseases or phenotypes
Gene Synonyms OMIM Disorder or phenotype
ABCA1 ABC1 600046 Familial HDL deﬁciency
Tangier disease
ABCA2 ABC2 600047 Alzheimer’s disease
ABCA3 ABC3 601615 Neonatal surfactant deﬁciency
ABCA4 ABCR 601691 Retinopathies
Macula degeneration
Cone-rod dystrophy
ABCA7 ABC7 605414 Sjo¨gren syndrome
ABCA12 ABC12 607800 Lamellar ichthyosis type II
Harlequin ichthyosis
ABCB1 MDR1 171050 Ulcerative colitis
ABCB2 TAP1 170260 Immune deﬁciency
ABCB3 TAP2 170261 Wegener-like granulomatosis
ABCB4 MDR3 171060 Progressive familial intrahepatic cholestasis type 3 (PFIC-3)
Intrahepatic cholestasis of pregnancy (ICP)
ABCB7 ABC7 300135 X-linked sideroblastosis and anemia (XLSA/A)
ABCB11 BSEP 603201 Progressive familial intrahepatic cholestasis type 2 (PFIC-2)
ABCC2 MRP2 601107 Dubin–Johnson syndrome (DJS)
ABCC6 MRP6 603234 Pseudoxanthoma elasticum (PXE)
ABCC7 CFTR 602421 Cystic ﬁbrosis (CF)
ABCC8 SUR1 600509 Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)
ABCC9 SUR2 601439 Dilated cardiomyopathy with ventricular tachycardia
ABCD1 ALD 300371 Adrenoleukodystrophy (ALD)
ABCD3 PXMP1 170995 Zellweger syndrome 2 (ZWS2)
ABCG2 MXR, BCRP 603756 Protoporphyria IX
ABCG5 White3 605459 b-Sitosterolemia
ABCG8 White 4 605460 b-Sitosterolemia
Fig. 1. ABCA3 and ABCA12 in lamellar body lipid metabolism. (A) Type II pneumocyte cells. (B) Keratinocytes. PUFA, poly unsaturated fatty
acids; PC, phosphatidylcholine; DPPC, dipalmitoyl-PC; MVE, multivesicular endosome; SR-BI, scavenger receptor-BI; TJ, tight junction; AJ,
adherens junction; D, desmosomes; CER, ceramide; CS, cholesterol sulfate.
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G. Schmitz et al. / FEBS Letters 580 (2006) 5597–5610 5601ABCA7 and the ﬁrst exon of the HA-1 gene [28]. In addition to
the major transcript form, a second main mRNA isoform
resulting from alternative splicing (termed type II mRNA) of
human ABCA7 has been detected [29]. A novel exon is located
between former exons 5 and 6, designated as exon 5B, and
contains two termination codons and another translation initi-
ation codon. Thus, translation of type II mRNA produces an
ABCA7 protein containing 28 novel N-terminal amino acids
instead of the 1–166 amino acid sequence in full length
(type I) ABCA7. Interestingly, most of type II ABCA7 is local-
ized intracellularly when expressed in HEK 293 cells, indicat-
ing that the N-terminal domain is important for traﬃcking
of ABCA7 to the plasma membrane. Tissue-speciﬁc RT-PCR
analysis has shown that the expression of type II mRNA is
higher than type I mRNA in spleen, thymus, lymph node,
and trachea, while type I mRNA was equal to or more than
type II mRNA in bone marrow and brain [29,30].
The detailed molecular function of the 127-kDa HA-1 minor
histocompatibility antigen is unknown, but it potentially trans-
ports minor histocompatibility peptides together with MHC
class I molecules via the Golgi complex to the cell surface,
where they are presented to T cells. In the case of HA-1, which
has properties of small G-protein family interacting proteins, a
deﬁned N-terminal nonapeptide bearing the His168Arg dimor-
phism has been identiﬁed as the target immune epitope recog-
nized by T cells [31]. Between ABCA7 and HA-1 genes a
functional and regulatory interlink might exist, which is espe-
cially interesting since ABCA7 has been shown to be regulated
by sterols via sterol-regulatory-element binding protein 2
(SREBP2) [32]. ABCA7/HA-1 may be involved in autoim-
mune disorders since both transcripts are expressed in macro-
phages and lymphocytes, major eﬀector cells of chronic
inﬂammation. Furthermore, a hallmark of autoimmune re-
lated diseases is disturbed autophagy of cell organelles and
thereby persistence of protein degradation products that un-
dergo antigen presentation. A polypeptide consisting of amino
acids 186–320 within the ﬁrst extracellular domain of ABCA7
encodes the autoantigen SS-N suggesting that ABCA7 is asso-
ciated with the pathogenesis of Sjo¨gren’s syndrome [33]. Fur-
thermore, recent studies revealed that the 168H variant of
the minor histocompatibility antigen HA-1 is associated with
reduced risk of primary Sjo¨gren’s syndrome [34] and that
ABCA7 is highly expressed in salivary glands of patients with
Sjo¨gren’s syndrome [35]. Recent data also indicate that
ABCA7 might be important for hematopoietic development,
diﬀerentiation, and immunological functions related to phago-
cytosis [32].2.4. ABCA12 and genetic keratinization disorders
The ABCA12 gene, which comprises 53 exons spanning
206 kb, has been mapped to chromosome 2q34, the region
for the keratinization disorder lamellar ichthyosis, an auto-
somal recessive form of ichthyosis characterized by whole
body skin desquamation [36,37]. Thereafter, missense muta-
tions in the ABCA12 gene have been identiﬁed [38] and two re-
cent independent studies demonstrated that mutations in the
ABCA12 gene also underlie the very severe form of another
keratinization disorder-harlequin ichthyosis [39,40]. Based on
the identiﬁed mutations, it can be assumed that the two clinical
phenotypes arise from diﬀerent alterations of the ABCA12
protein causing either the severe form harlequin ichthyosis orthe milder form manifesting as lamellar ichthyosis type 2. Dur-
ing keratinocyte diﬀerentiation, lipids accumulate in lamellar
granules which are extruded in the intercellular space for enzy-
matic modiﬁcation to produce a water permeability barrier
consisting of ceramides, cholesterol and saturated long-chain
fatty acids [41]. ABCA12 is present in the upper epidermal
layer in lamellar granules of normal epidermal keratinocytes
and likely functions in the secretion of lipids [39] (Fig. 1B).
Keratinocytes from patients with harlequin ichthyosis display
an accumulation of glucosylceramide around the nuclei and
ABCA12 gene transfer into deﬁcient cells normalizes glucosyl-
ceramide staining present in healthy keratinocytes, assuming
that ABCA12 is involved in the intracellular translocation of
lamellar granule sphingolipids [39].2.5. ABCB4 (MDR3) and ABCB11 (BSEP) in progressive
familial intrahepatic cholestasis (PFIC)
Mutations in three hepatic canalicular membrane proteins
have been identiﬁed that result in cholestasis and later chronic
liver disease. These three diseases are progressive familial
intrahepatic cholestasis (PFIC) types 1, 2 and 3 and are caused
by mutations in the genes coding for the familial intrahepatic
cholestasis 1 protein (FIC1), and the ABC-transporters bile
salt export pump (BSEP, ABCB11) and the phospholipid
translocase MDR3 (ABCB4), respectively [42]. Ten autosomal
recessive mutations in the coding region of the ABCB11
(BSEP) gene have been reported so far in diﬀerent PFIC2 pa-
tients. ABCB11 is the major bile salt carrier in the canalicular
membrane and mutations very often cause low expression or
aberrant membrane localization [43]. PFIC3 is also an auto-
somal recessive disorder and the ABCB4 (MDR3) gene local-
izes to chromosome 7q21. In most cases where mutations
causing truncations occur in the gene, a complete loss of
ABCB4 protein at the canalicular membrane has been ob-
served, whereas low expression levels correlate with missense
mutations [44]. The function of ABCB4 protein was analyzed
in a knock-out model with deletion of the mouse homolog
(mdr2). These knock-out mice had a lack of phospholipid
translocation into bile, normal bile acid secretion, progressive
liver disease, and histology consistent with PFIC3 patients
leading to the assumption that ABCB4 is a phosphatidylcholine
translocase [45]. The purpose of phospholipids in bile is to form
micelles with bile acid and to prevent crystallization of choles-
terol. Without the formation of micelles with bile acids, the del-
eterious detergent eﬀect of bile acids on the biliary epithelium
and cholangiocytes is not prevented and causes PFIC.2.6. ABCD1 in adrenoleukodystrophy
The X-linked adrenoleukodystrophy (ALD) is an inherited
peroxisomal disorder caused by mutations in ABCD1 (Table 2)
resulting in progressive neurological dysfunction, occasionally
associated with adrenal insuﬃciency [46]. ALD is character-
ized by the accumulation of unbranched saturated fatty acids
with a chain length of 24–30 carbons, particularly hexacosano-
ate (C26), in cholesteryl esters of brain white matter and in
adrenal cortex and in certain brain sphingolipids. Adreno-
leukodystrophy belongs to a group of defects in peroxisomal
b-oxidation [47]. The ﬁrst step in the oxidation of very-long-
chain fatty acids (VLCFA) involves the activation by conver-
sion into CoA esters and the transport into peroxisomes [48].
The ABCD1 protein mediates this transport process as
5602 G. Schmitz et al. / FEBS Letters 580 (2006) 5597–5610evidenced by overexpression of human cDNAs encoding the
ABCD1 protein and its closest relative, the ABCD2 (ALDR)
protein in ﬁbroblasts of ALD patients [49]. The accumulation
of very-long-chain fatty acids could also be prevented by over-
expression of the ABCD2 protein in immortalized ALD cells
and the peroxisomal b-oxidation defect in the liver of
ABCD1-deﬁcient mice could be restored by stimulation of
ABCD2 and ABCD4 gene expression through treatment with
fenoﬁbrate [49]. These results implicate that a therapy of adre-
noleukodystrophy might be possible by drug-induced overex-
pression or ectopic expression of ABCD genes.2.7. ABCG5 and ABCG8 in b-Sitosterolemia
ABCG5 and ABCG8 have been recently implicated in the ef-
ﬂux of dietary sterols from intestinal epithelial cells back into
the gut lumen and from the liver to the bile duct. These mech-
anisms are disrupted in b-Sitosterolemia or phytosterolemia or
shellﬁshsterolemia, a rare autosomal recessive disorder. The
disease is characterized by enhanced trapping of cholesterol
and other sterols, including plant and shellﬁsh sterols, within
the intestinal cells and the inability to concentrate these sterols
in the bile. As a consequence aﬀected individuals have strongly
increased plasma levels of plant sterols e.g. b-sitosterol, cam-
pesterol, stigmasterol, avenosterol, and 5a-saturated stanols,
whereas total sterol levels remain normal or are just moder-
ately elevated [50]. Using a combination of positional cloning,
genome database survey as well as DNA-microarray analysis,
Lee et al. [51] and Berge et al. [52] identiﬁed ABCG5 and
ABCG8 mutations in b-Sitosterolemia patients. ABCG5 and
ABCG8 have a bi-directional promoter and share common
regulatory elements [53]. The highest expression level of both
transporters is found in liver and intestine and high-cholesterol
diet feeding in mice induces the expression of both genes.
These ﬁndings together with the observed clinical and bio-
chemical features of b-Sitosterolemia patients assume that
ABCG5 and ABCG8 play an important role in reducing intes-
tinal absorption and promote biliary excretion of sterols. Until
today several mutations and a number of polymorphisms have
been identiﬁed in ABCG5 and ABCG8 [54]. A striking ﬁnding
is that mutations in b-Sitosterolemia patients occur exclusively
either in ABCG5 or ABCG8, but never in both genes together.
ABCG5 and ABCG8 proteins form a functional heterodimer
to transport plant sterols directly back to the gut lumen as a
kick-back mechanism, which may also eﬄux cholesterol, there-
by regulating total sterol absorption. In the liver, expression of
ABCG5 and ABCG8 functions in regulating biliary cholesterol
secretion [55–57], which also requires biliary phospholipid
transport by ABCB4 [58].3. Regulation, traﬃcking, and function of ABCA1 and ABCG1
in lipid metabolism
ABCA1 is crucial for the eﬄux of phospholipids and sterols
to apoA-I containing HDL precursors. Like Tangier disease
patients, ABCA1 knockout mice exhibit HDL deﬁciency and
have strongly reduced cellular lipid eﬄux activity [59]. Total
body and selective hepatic overexpression of ABCA1 in mice
results in an increase of HDL [60] and conversely, HDL levels
are strongly reduced in mice with a liver-selective deletion of
ABCA1 [61]. There is increasing evidence that in addition tothe liver, intestinal ABCA1 expression is a rate-limiting factor
for plasma HDL production [62]. Although ABCA1 in macro-
phages has little inﬂuence on HDL, it is an important factor in
the prevention of foam cell formation of macrophages in the
arterial wall [63]. To control lipid eﬄux, ABCA1 is tightly reg-
ulated at the level of transcription and translation. The major
human ABCA1 gene promoter was ﬁrst reported upstream of
exon 1 (221 bp) followed by a 24-kb intron 1 [64,65]. Cavelier
et al. [66] have identiﬁed an alternative exon 1 (exon 1a),
136 bp in length and located 2210 bp upstream of exon 2. This
alternative transcript contains the entire coding sequence of
human ABCA1 and is expressed in testis and liver but not
macrophages. Upstream of exon 1a, an alternative promoter
that contains a TATA box and CAAT sites as well as other po-
tential binding sites for sterol-sensing nuclear receptors was
identiﬁed. The importance of this alternative promoter in reg-
ulating ABCA1 gene expression, however, has to be deter-
mined in human tissues [67]. ABCA1 gene expression is
stimulated by liver-X-receptors (LXRs) and the retinoid-X-
receptor (RXR) which form heterodimers and are activated
by oxysterols and retinoids, respectively. In macrophages,
the physiological ligand for LXRa and LXRb is 27-hydroxy-
cholesterol, which is produced by the mitochondrial 27-choles-
terol hydroxylase (CYP27). In addition to the induction of
ABCA1 expression, cAMP also stimulates ABCA1 phosphor-
ylation [68,69]. Interestingly, apoA-I activates cAMP signal-
ling and thereby the phosphorylation of ABCA1. Janus
kinase 2 (JAK2) also phosphorylates ABCA1 [70], whereas
in the absence of apolipoproteins, phosphorylation of the
ABCA1 PEST motif is a signal for calpain-mediated degrada-
tion of ABCA1 [71] (Fig. 2). Furthermore, ABCA1 protein
destabilization is performed by unsaturated fatty acids via a
phospholipase D2-dependent pathway [72,73].
ABCA1, which has also a conserved N-terminal dileucine
motif, assembles functional complexes with heteromeric pro-
teins and the intracellular targeting of ABCA1 is regulated
by diverse traﬃcking proteins (Fig. 2). The Rho family
GTPase cdc42 directly interacts with ABCA1 to control
ﬁlopodia formation and intracellular lipid transport [74,75].
Furthermore, the PDZ-domain proteins b2-syntrophin, a1-
syntrophin, and Lin7 bind to the KESYV-motif at the C-ter-
minus of ABCA1 and regulate its targeting via vesicular
traﬃcking, turnover, and intracellular localization in polarized
cells [76,77]. The ADP-ribosylation factor (ARF)-like 7
(ARL7) is involved in vesicular budding from the trans-Gol-
gi-network and has been implicated in the intracellular translo-
cation of lipids via ABCA1 and the secretory lysosome
pathway [78]. Along with these ﬁndings, the phagosomal pro-
teins syntaxin 13 and ﬂotillin 1 form a complex with ABCA1 in
plasma membrane raft microdomains and thereby modulate
phospholipid and cholesterol eﬄux [79]. Syntaxin 13 and its
interacting protein pallidin are major constituents of the adap-
ter protein 3 (AP3) pathway and the AP3/secretory lysosome
pathway seems to play a major role in ABCA1-dependent lipid
traﬃc.
The cell-type expression and lipid-sensitivity of the half-size
transporter ABCG1 is very similar to ABCA1 although the
transcriptional regulation of ABCG1 is very complex and mul-
tiple alternative promoters and mRNA isoforms exist [80–83].
A comparison of human and murine orthologue promoter se-
quences and cDNAs suggests that one major transcript
(termed ABCG1a) is expressed in most tissues, whereas the
Fig. 2. Domain structure of ABCA1 and sites regulating turnover, traﬃcking and function. The amino acid numbers denominate transmembrane
domains. NBD, nucleotide binding domains; A, B, Walker A/B motifs; S, signature motif.
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forms, which diﬀer at the N-terminus of ABCG1 remains to
be determined. A striking similarity between human ABCG1
and Drosophila ABCG transporters (white, brown, scarlet
and E23) is their transcriptional regulation by nuclear hor-
mone receptors and their potential cellular localization. Dro-
sophila white and scarlet proteins are involved in the
formation of eye color pigments by the transport of 3-hydr-
oxykynurenine from the cytoplasm into pigment granules. The
garnet gene product, which also modulates eye color biogene-
sis of Drosophila, shows strong homology with the delta sub-
unit of the human AP-3 complex, which is mainly associated
with the trans-Golgi network and other peripheral membranes
[84]. This adaptor complex is involved in intracellular targeting
of proteins to specialized vesicular compartments and these
proteins often harbor dileucine motifs, which are recognized
by the AP-3 complex. A sequence alignment of white, brown,
and scarlet from Drosophila and human ABCG proteins re-
veals a conserved region near the ﬁrst membrane domain con-
taining a putative dileucine motif [85]. These ﬁndings raise the
possibility that ABCG1 and other family members may inter-
act with AP-3 in order to reach their subcellular compartment
and that the diﬀerent ABCG1 protein isoforms might be tar-
geted to diﬀerent intracellular compartments.
ABCG1-speciﬁc antisense oligonucleotides signiﬁcantly im-
paired cholesterol and phospholipid eﬄux to HDL3 [86]. In
HEK293-cells, transient overexpression of murine ABCG1 or
ABCG4 caused a strong increase in HDL-dependent choles-
terol eﬄux and RNA interference-directed against macro-
phage ABCG1 mRNA also resulted in diminished lipid eﬄux
[87]. Interestingly, in ABCG1 overexpressing cells, lipid-poor
apoA-I was ineﬀective in lipid deloading of cells, which indi-
cates that, in contrast to ABCA1, acceptor-particles for
ABCG1-derived lipids are more mature a-HDL subclasses
(HDL3 and HDL2) than preb-HDL [87]. Human recombinantABCG1 and ABCG4 expressed in Sf9 cells both display ATP
binding and hydrolysis with a signiﬁcant higher activity of
ABCG1 compared to ABCG4. Importantly, co-expression of
a catalytic site mutant of ABCG4 showed a dominant negative
eﬀect and selectively abolished the ATPase activity of ABCG1
[88]. Therefore, it can be concluded that ABCG1 may either
act as a homodimer in the absence of ABCG4 or function as
a heterodimer in combination with ABCG4 in coexpressed tis-
sues to increase lipid eﬄux. Informations about the in vivo
function of ABCG1 came from a recent study with ABCG1
knockout mice, showing that cholesterol, triglyceride, and
phospholipid concentrations were signiﬁcantly increased in
the liver and lung of Abcg1-null mice fed the high-fat/high-
cholesterol diet, as compared to their wild-type littermates
[89]. Despite the lack of changes in plasma lipid levels, macro-
phage foam cells highly enriched in lipid droplets and choles-
terol crystals were observed in the lung of Abcg1-null mice.
These ﬁndings are in contrast to earlier reports showing that
plasma HDL and cholesteryl ester levels were reduced by infu-
sion of mice with adenovirus expressing ABCG1 [90], which
might result from artiﬁcally high overexpression of ABCG1
in hepatocytes [91].
There is little doubt that ABCA1 interacts directly with
apoA-I. Moreover, there is evidence that ABCA1 modulates
the internalization of apoA-I for lipidation and resecretion
(retroendocytosis). For the ﬁrst time the HDL retroendocyto-
sis pathway was suggested by Schmitz et al. in 1985 [92] using
electron microscopy and gold-conjugated HDL particles.
Beside a saturable HDL binding to macrophages loaded with
cholesterol, gold-labeled HDL were endocytosed via coated
pits and resecreted into the culture medium without degrada-
tion. Furthermore, apoA-I and ABCA1 colocalise in endocytic
compartments [93,94]. Additionally, there is evidence that
apoA-I binding to ABCA1 occurs at cholesterol/sphingomye-
lin rich membrane domains. Although, ABCA1 is excluded
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methods, some ABCA1 was detected in Lubrol-resistant mem-
branes [95,96]. Moreover, apoA-I interaction with plasma
membrane lipid rafts controls cholesterol export from macro-
phages [97] and sphingomyelinase treatment, which also dis-
rupts rafts, inhibited cholesterol eﬄux to apoA-I [98]. Thus,
an early apoA-I interaction with lipid rafts seems to be essen-
tial for eﬄux initiation, although the majority of exported cho-
lesterol and phospholipids may not originate from raft
domains [97] (Liebisch et al. unpublished observation).
Together with recent data from Gelissen et al. [99] showing
that overexpression of ABCG1 promotes cholesterol eﬄux not
only to HDL but also to other lipid acceptors like phosphati-
dylcholine vesicles, a two-step model for ABCA1 and ABCG1
mediated cellular lipid eﬄux could be proposed: Initially
ABCA1 may promote cholesterol and phospholipid eﬄux
involving membrane microdomains to lipid-poor apoA-I and
ABCG1 subsequently promotes the eﬄux of additional cellular
cholesterol to preformed lipid–protein complexes.4. Novel lipidomic technologies
4.1. mRNA detection by realtime RT-PCR and DNA
microarrays
Quantitative realtime reverse transcription PCR (RT-PCR)
is a fast and sensitive detection method which allows reproduc-
ible quantiﬁcation of minute amounts of RNA. Total RNA
from tissue specimens or single cells is reverse transcribed to
generate cDNA as a template for quantitative PCR. Two dif-
ferent approaches have been reported to quantify all known
human ABC transporters in tissue samples with highly active
lipid metabolism and tumor cell lines [17,100]. We have devel-
oped a rapid, speciﬁc and sensitive realtime RT-PCR method
to monitor the mRNA levels of 47 human ABC transporters
based on the TaqMan technology using speciﬁc primers
and probes and 50 ng of total RNA [17]. We have recently ex-
tended, improved and simpliﬁed the quantiﬁcation of all 47
ABC transporters by creating a Human ABC Transporter
TaqMan Low Density Array based on an Applied Biosystems
7900HT Micro Fluidic Card [101]. The method allows simulta-
neous analysis of all 47 human ABC transporters and the ref-
erence gene 18S rRNA in two replicates of four diﬀerent
samples per run in a 2 ll small-volume format. Transcript pro-
ﬁling in macrophages has revealed several novel LXR/RXR
regulated ABC transporters including ABCB1 (MDR1),
ABCB9, ABCB11 (BSEP), ABCC2 (MRP2), ABCC5
(MRP5), ABCD1 (ALD), ABCD4, and ABCG2. This assay
will be a very useful tool to monitor dysregulated ABC trans-
porter mRNA proﬁles in human lipid disorders and cancer-re-
lated multidrug resistance. Furthermore, the pharmacological
and metabolic regulation of ABC transporter expression
important for drug development could be analyzed in large
screening approaches using this method.
In a recent report by Szakacs et al. the expression levels of
the same gene panel was measured by realtime RT-PCR using
SYBR Green and the LightCycler instrument with 150 ng
RNA template. Although less speciﬁc and more laborious than
our TaqMan approach, the LightCycler assay was success-
fully used to correlate the mRNA expression pattern of ABC
transporters with anticancer drug response in 60 diverse cancer
cell lines [100].DNA microarrays are now frequently applied for the fast
detection of expression levels of a large number of genes simul-
taneously and the generation of molecular ﬁnger prints [102].
A speciﬁc microarray dedicated to ABC transporters has been
recently published by Annereau and coworkers [103]. This
ABC-ToxChip contains cDNA probes and 70mer oligonucleo-
tides targeting 36 human ABC transporters and speciﬁc over-
expression of ABCB1 and ABCC2 could be detected in
tumor cells [103]. Huang et al. developed a 70mer oligonucleo-
tide microarray covering 40 ABC transporters and ABCB1,
ABCC3, and ABCB5 expression was negatively correlated
with drug resistance, implicating ABCB5 as a novel chemore-
sistant factor [104]. In another approach, a low-density cDNA
microarray for 38 human ABC transporters, termed DualChip
human ABC, was produced and validated in multidrug-resis-
tant sublines previously shown to overexpress ABCB1,
ABCC1, or ABCG2 [105]. These results demonstrate the proof
of principle for successful microarray expression analysis of
ABC transporters, which provide abundant amount of RNA.
However, the limited sensitivity, e.g. the requirement of
25 lg total RNA for one ABC-ToxChip assay or of 1 lg
mRNA for the DualChip human ABC, speciﬁcity problems
with highly homologous DNA sequences, and the lack of stan-
dardization are major drawbacks limiting the application of
this methodology in lipidomics research. In conclusion, among
the published ABC-transporter mRNA proﬁling assays, the
Taqman microﬂuidic card assay optimally fulﬁlls good labora-
tory practice (GLP) criteria concerning speciﬁcity, sensitivity
and accuracy and thereby can be regarded as a reference assay
for mRNA expression analysis of this gene group.4.2. Lipid species analysis by mass spectrometry
The introduction of soft ionisation techniques like electro-
spray ionization (ESI) revolutionized the ﬁeld of lipid analysis
making polar lipids accessible to mass spectrometric analysis.
Now numerous methodologies have been developed for both
the structural analysis of complex lipids as well as quantitative
proﬁling of complex lipid mixtures (for reviews see phospho-
lipids [106,107], sphingolipids [108], glycosphingolipids [109],
prostaglandins [110]).
In the late 90s it became clear that nano electrospray ioniza-
tion tandem mass spectrometry (ESI-MS/MS) permits a direct
quantiﬁcation of the major phospholipid classes from a minute
amount of material without separation of crude lipid extracts
[111]. These methods could be used in a high sample through-
put either by direct ﬂow injection analysis [112–114] or using
an automated nanospray chip ion source [115–117]. To per-
form high throughput quantiﬁcation of lipid species an auto-
mated data analysis is a prerequisite including the correction
of isotope overlap [113], species assignment [118] as well as
quantiﬁcation.
Analysis of unseparated lipid extracts by mass spectrometry
may be hampered by signal suppression eﬀects due to other
lipid components as well as lack of speciﬁcity in the presence
of isobaric molecules or uncharacteristic molecule fragmenta-
tion. Therefore, sample separation prior analysis either by di-
rect mass spectrometer coupling or oﬄine separation are used.
Beside classical approaches like liquid and gas chromatogra-
phy coupling to mass spectrometry, capillary electrophoresis
is increasingly applied especially in the ﬁeld of glycosphingo-
lipid analysis [109].
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lipid eﬄux to apoA-I and HDL, which is related to ABCA1
and ABCG1 function (Schiﬀerer et al. submitted JBC). Both
free cholesterol (FC) loaded human primary ﬁbroblasts and
human monocyte-derived macrophages loaded with enzymati-
cally modiﬁed LDL (E-LDL) revealed a higher apoA-I speciﬁc
eﬄux for monounsaturated phosphatidylcholine (PC) species
together with a decreased contribution of polyunsaturated
PC species. Moreover, medium chain sphingomyelin (SM) spe-
cies SM 14:0 and SM 16:1 were translocated preferentially to
apoA-I in both cell types. In contrast to ﬁbroblasts, mono-
cyte-derived macrophages displayed a considerable proportion
of cholesteryl esters (CE) in basal and apoA-I speciﬁc eﬄux
media, most likely due to secretion of CE associated to apoE.
Analysis of HDL3 mediated lipid eﬄux from monocyte-
derived macrophages using D9-choline and
13C3-FC stable
isotope labeling revealed signiﬁcantly diﬀerent D9-PC and
D9-SM species pattern for apoA-I and HDL3 speciﬁc media,
which indicates a contribution of distinct cellular phospholipid
pools to apoA-I and HDL3 mediated eﬄux. This example
shows that a detailed lipid species analysis by ESI-MS/MS
may provide an even more powerful tool to understand cellu-
lar lipid transport mechanism also related to ABC transporter
function.
Several ABC transporters are involved in the formation of
bile (ABCB4 [58], ABCB11 [42], ABCG5, ABCG8 [55–57]).
Mass spectrometric techniques could serve to further analyze
the detailed composition of lipid species secreted into the bile,
which may together with biophysical models help to further
understand the formation of toxic bile. Lipid species analysis
may include bile acids and their conjugates, which may be ana-
lyzed by LC-MS/MS [119]. Additionally, phytosterol analysis,
which may be useful also in plasma, could be achieved by LC-
MS/MS using atmospheric pressure photoionization (APPI)
[120]. Another important aspect related to bile formation is
the biosynthesis of PC the main substrate of ABCB4 in the
liver. PC can be derived from either choline and can be con-
verted to PC via the CDP-choline pathway or be generated
via methylation of phosphatidylethanolamine (PE) by the en-
zyme PE N-methyltransferase (PEMT)[121] . Moreover it has
been shown that the PC/PE ratio is a key regulator of cell
membrane integrity and plays a role in the progression of ste-
atosis into steatohepatitis [122]. In this respect a detailed inves-
tigation of phospholipid metabolism using stable isotope
labeling and ESI-MS/MS analysis may shed further light on
mechanisms [123,124].
One major problem of these novel mass spectrometry based
lipidomic techniques is the vast amount of data generated. Be-
cause commercial software for lipidomic analysis is so far not
available, most groups use self-made data analysis programs.
These tools are used for raw data processing as well as species
assignment and quantiﬁcation. Software assistance are re-
quired even more to analyze metabolic data of single lipid
species, e.g. by stable isotope labelling.
Finally, classical approaches like gas chromatography [125]
or novel approaches based on LC-MS/MS [126] may be used
to detect very long-chain fatty acids (VLCFA) in plasma and tis-
sues indicating X-linked adrenoleukodystrophy (ABCD1) [48].
In general lipid mass spectrometric techniques may be used
in the diagnosis of ABC transporter related disorders as well
as to discover lipid species transported by ABC or to unravel
ABC transporter function.4.3. Fluorescence imaging and ﬂow cytometry
To characterize ABC transporter function ﬂuorescent imag-
ing methods are important to deﬁne tissue and subcellular
localization including lipid domains, colocalization with other
proteins as well as traﬃcking of ABC transporters. Frequently
fusion proteins with green ﬂuorescent protein (GFP) were used
to detect the subcellular localization of ABC transporters, e.g.
localization of ABCA1 on basolateral surface in hepatocytes
[127] and Caco-2 cells [128]. Neufeld et al. performed an ele-
gant study to investigate the complex intracellular traﬃcking
of ABCA1 using a ABCA1-GFP fusion protein and confocal
microscopy also in time-lapse image acquisition mode [93].
The importance of the ABCA1-PEST domain for posttransla-
tional modiﬁcation and intracellular shuttling of ABCA1
could be shown by immunoﬂuorescence confocal microscopy.
While wild type ABCA1 showed both plasma membrane local-
ization and substantial colocalization with LAMP2 in late
endosomes, PEST domain deleted ABCA1 revealed more
prominent plasma membrane localization but little colocaliza-
tion with LAMP2 [129]. Experiments evaluating the binding of
Cy5-apoA-I and Cy5-annexin V argue against a role of phos-
phatidylserine translocation in the apoA-I mediated lipid eﬄux
[130]. Moreover, the abundance and localization of protein
isoforms can be evaluated by immunoﬂuorescence confocal
microscopy as for example the cellular localization of type I
(cell surface and intracellularly) compared to type II (intracel-
lularly) ABCA7 [29].
An important goal to analyze lipid transport as well as
metabolism is to visualize lipids in their subcellular compart-
ments. A frequently used approach uses ﬂuorescent labeled
lipid probes. For example sphingolipid analogs labeled with
NBD or BODIPY containing fatty acids are internalized by
endocytosis and subsequently sorted and transported to vari-
ous intracellular compartments [131]. However, the bulky ﬂuo-
rescent groups may change the biophysical behaviour of the
lipid probes showing a diﬀerent behaviour compared to their
natural analogues. An excellent example of lipid probes mim-
icking the conformation of their natural counterparts are poly-
ene-fatty acids described by Ku¨rschner et al. [132].
Another important issue of lipid imaging is the detection of
lipids rafts or plasma membrane microdomains. Several lipid
probes have been described to monitor lipid components of
rafts, e.g. lysenin, a sphingomyelin-binding protein obtained
from an earthworm as well as a ﬂuorescein ester of poly(ethyl-
eneglycol) cholesteryl ether (fPEG-Chol) were described to
partition into cholesterol-rich membranes [133]. Other fre-
quently used probes to monitor ‘‘raftophilic’’ lipid species
are cholera toxin for ganglioside GM1 [134] and cholesterol
binding protein perfringolysin O (theta-toxin) [135]. Moreover,
the single-molecule tracking of labeled lipid molecules like
dioleoylphosphatidylethanolamine [95,136] or other mem-
brane molecules may give novel insights into membrane com-
partmentalization and the dynamic assembly of large
molecular complexes potentially clustered in rafts [137].
A convenient technique to quantify surface expression of lip-
ids and lipid-modiﬁed proteins is ﬂow cytometry. For instance
phosphatidylserine translocation to the outer plasma mem-
brane leaﬂet by annexin V staining is frequently used assay
to investigate apoptosis. Furthermore, cell surface expression
of membrane ceramide, lactosylceramide and more complex
glycosphingolipids was analyzed by ﬂow cytometry [138]. In
a combination of quantitative ﬂow cytometry and lipid
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primary macrophages with enzymatically degraded low density
lipoprotein (E-LDL) or oxidized LDL (Ox-LDL) induces dif-
ferent membrane microdomains.
A commonly used technique to study interactions between
molecules is ﬂuorescence resonance energy transfer (FRET).
This method can also be combined with ﬂow cytometry, e.g.
for the investigation of lipopolysaccharide and ceramide in-
duced clustering of the LPS receptor CD14 with other signal-
ing receptors [139]. Finally, ﬂow cytometry may be used to
investigate the detergent insolubility of membrane markers,
which has been used for a rapid screening of raft-association
of blood monocyte surface antigens [140].5. Conclusions
Human ABC-transporters are associated with several mono-
genic and polygenic disorders. Disease phenotypes have greatly
expanded the knowledge about their physiological roles in lipid
metabolism as well as their precise mechanisms of action. Novel
lipidomic high-throughput technologies are valuable tools for
researchers to study and deﬁne important transcriptional regu-
lators, intracellular routing steps and transported lipid molecule
species. These ﬁndings will help to develop pathophysiological
concepts and moreover will allow to improve diagnosis and
therapy of ABC-transporter related lipid disorders.
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